Cargando…

Post-licensing safety of fosamprenavir in HIV-infected children in Europe†

PURPOSE: Fosamprenavir, combined with low-dose ritonavir (FPV/r), is indicated for treatment of HIV-infected children aged ≥6 years in Europe. Our purpose was to assess the safety of licensed use of FPV/r in HIV-infected children reported to six cohorts in the European Pregnancy and Paediatric HIV C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Judd, Ali, Duong, Trinh, Galli, Luisa, Goetghebuer, Tessa, Ene, Luminita, Julian, Antoni Noguera, Amador, Jose Tomas Ramos, Pimenta, Jeanne Marie, Thorne, Claire, Giaquinto, Carlo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265189/ https://www.ncbi.nlm.nih.gov/pubmed/24741696 http://dx.doi.org/10.1002/pds.3543

Ejemplares similares

HCV treatment in children and young adults with HIV/HCV co-infection in Europe
por: Turkova, Anna, et al.
Publicado: (2015)

Outcomes of etravirine-based antiretroviral treatment in treatment-experienced children and adolescents living with HIV in Europe and Thailand
por: Lyons, Alex, et al.
Publicado: (2022)

Children living with HIV in Europe: do migrants have worse treatment outcomes?
por: Chappell, Elizabeth, et al.
Publicado: (2021)

Long-term trends in mortality and AIDS-defining events after combination ART initiation among children and adolescents with perinatal HIV infection in 17 middle- and high-income countries in Europe and Thailand: A cohort study
por: Judd, Ali, et al.
Publicado: (2018)

Once-daily fosamprenavir with ritonavir in the treatment of HIV infection in therapy-naïve patients
por: Flamholc, Leo, et al.
Publicado: (2008)

Prevalence of resistance and HIV-1 protease mutation patterns after failures with fosamprenavir-containing regimens
por: Marcelin, AG, et al.
Publicado: (2010)

Treatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing Antiretroviral Regimens
por: Ross, Lisa L, et al.
Publicado: (2015)

Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children – a EuroCoord-CHAIN-EPPICC joint project
por: Ngo-Giang-Huong, Nicole, et al.
Publicado: (2016)

Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population
por: Rusconi, Stefano, et al.
Publicado: (2012)

SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients
por: Kumar, P, et al.
Publicado: (2010)

A review of the changes to the licensing of influenza vaccines in Europe
por: Wijnans, Leonoor, et al.
Publicado: (2015)

Changes in lipid profiles after switching to a protease inhibitor-containing cART - unfavourable effect of fosamprenavir in obese patients
por: Gyalrong-Steur, M, et al.
Publicado: (2011)

Pharmacokinetics and 48-week Safety and Antiviral Activity of Fosamprenavir-containing Regimens in HIV-infected 2- to 18-year-old Children
por: Fortuny, Claudia, et al.
Publicado: (2014)

Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT
por: Smith, Kimberly Y, et al.
Publicado: (2008)

Pharmacokinetics, Safety and Antiviral Activity of Fosamprenavir/Ritonavir-containing Regimens in HIV-infected Children Aged 4 Weeks to 2 Years—48-week Study Data
por: Cotton, Mark, et al.
Publicado: (2014)

Availability and Use of Molecular Microbiological and Immunological Tests for the Diagnosis of Tuberculosis in Europe
por: Tebruegge, Marc, et al.
Publicado: (2014)

Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results
por: Kumar, Princy, et al.
Publicado: (2013)

License to glue
por: Wells, William A.
Publicado: (2004)

Franchising & Licensing
por: SHERMAN, Andrew
Publicado: (2011)

Literature and License
Publicado: (1921)

Fraudulent Licenses
por: Nolan, C. T.
Publicado: (1916)

Liquor License
Publicado: (1858)

Liquor License
Publicado: (1876)

Teaching and Licensing
Publicado: (1880)

A License to Practice Medicine Cannot Be a License to Harm
por: Schluger, Neil W., et al.
Publicado: (2022)

High Incidence of Group B Streptococcal Infection in Infants Born to HIV-Infected Mothers
por: Goetghebuer, Tessa, et al.
Publicado: (2012)

An unused license to fire
por: Tuma, Rabiya S.
Publicado: (2006)

Tobacco – License to kill?
por: Damle, SG
Publicado: (2012)

Licensed Homes for Inebriates
por: Temple, Beatrice B., et al.
Publicado: (1913)

Rethinking origin licensing
por: Bell, Stephen P
Publicado: (2017)

Pay No License Fees
por: Crouse, J. N.
Publicado: (1903)

Separation of Teaching and Licensing
Publicado: (1851)

Interstate Reciprocity in Licensing
por: Potter, William Warren
Publicado: (1906)

State License for Nurses
Publicado: (1902)

State Examinations for License
Publicado: (1894)

State Examination for License
Publicado: (1893)

Shall Midwives Be Licensed?
Publicado: (1885)

Multiplying Licensing Boards
Publicado: (1905)

Licensing Medical Practitioners
por: Billings, Frank
Publicado: (1888)

Resolution on Interchange of License
Publicado: (1903)

Cannot write session to /tmp/vufind_sessions/sess_en5kt2ht3u0oui8lh1c8drkhre